TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05384743
Drug: Rituximab Monotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
Study: NCT06570213
Drug: Stellate Ganglion Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stellate Ganglion Blocks are an injection of local anesthetic into the stellate ganglion, a collection of nerves in the side of the neck.
Study: NCT05582837
Drug: nortriptyline + topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nortriptyline (7.5mg) + topiramate (10mg) taken 1x per day and escalate weekly as needed for 8 weeks
Study: NCT05101291
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
Study: NCT06220344
Drug: Iodine Dressing
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
Study: NCT02005523
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06607744
Drug: Pharmacokinetic profiles of Selegiline TDS and EMSAM
Normalized name: selegiline Transdermal System [Emsam]
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
Study: NCT06608212
Drug: Finerenone (Kerendia, BAY948862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Follow clinical practice/administration.
Study: NCT06608212
Drug: Others except finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
Study: NCT06664879
Drug: MBG-453 + Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously (by vein)
Study: NCT06756035
Drug: CT-95
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV dosing
Study: NCT06674460
Drug: Edaravone Dexborneol Sublingual Tablets
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.
Study: NCT05757999
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
Study: NCT05757999
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
Study: NCT05386433
Drug: Paxlovid
Normalized name: Paxlovid
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.
Study: NCT06512766
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study: NCT06512766
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study: NCT04850911
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
Study: NCT06684028
Drug: 68Ga-FAPI-JNU
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
Study: NCT03861676
Drug: (18F)DCFPyL
Normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-DCFPyl PET/CT scan
Study: NCT05292404
Drug: alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
Study: NCT06066112
Drug: Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
Study: NCT05044169
Drug: Broncho-Vaxom
Normalized name: Broncho-Vaxom
DrugBank: OM85 (DB16533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration for 6 months after remmission
Study: NCT04988607
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
Study: NCT04988607
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
Study: NCT04988607
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib is dosed orally at 80 mg once per day
Study: NCT06243835
Drug: Kindolor Tosylate
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kindolor Tosylate enteric coated tablets containing the specified amount of drug product
Study: NCT04634539
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
Study: NCT04634539
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
Study: NCT04634357
Drug: ET140203 T Cells
Normalized name: tisagenlecleucel
DrugBank: ET140203 (DB17196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
Study: NCT05589181
Drug: High Dose Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
Study: NCT05589181
Drug: Standard Buprenorphine Dose
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
Study: NCT05774691
Drug: Protamine sulfate
Normalized name: Protamine Sulfate
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
Study: NCT05774691
Drug: Protamine sulfate
Normalized name: Protamine Sulfate
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective protamine administration, in case of (threatening) bleeding
Study: NCT04404400
Drug: Investigational products administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational products include:~* Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~* 9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off.
Study: NCT05823506
Drug: PDE5 inhibitor (tadalafil)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
Study: NCT06569537
Drug: Lidocaine topical
Normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4%
Study: NCT04874038
Drug: Lidocaine 20mg/ml
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
Study: NCT05483543
Drug: Pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
Study: NCT05435248
Drug: HS-10375
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10375 will be administered orally once daily in a continuous regimen
Study: NCT05874245
Drug: oral Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
Study: NCT05874245
Drug: oral ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
Study: NCT05874245
Drug: oral Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
Study: NCT05219877
Drug: Pre-urodynamic Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
Study: NCT00099879
Drug: BMS-275183
Normalized name: BMS-275183
DrugBank: BMS-275183 (DB12144)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05850585
Drug: Fecal microbiota transplantation(FMT)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
Study: NCT05219877
Drug: Post-urodynamic Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
Study: NCT05187338
Drug: ipilimumab +pembrolizumab +durvalumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks.
Study: NCT00111943
Drug: 1% tenofovir gel
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06431919
Drug: Carvedilol 3.125 mg
Normalized name: carvedilol 3.125 MG
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
Study: NCT02985658
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit
Study: NCT02985658
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
Study: NCT02985658
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
Study: NCT06189040
Drug: BNT162b2 6µg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intradermal administration of 6µg
Study: NCT06189040
Drug: mRNA-1273 100µg
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular administration of 100µg
Study: NCT06189040
Drug: mRNA-1273 50µg
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular administration of 50µg
Study: NCT06189040
Drug: ChAdOx1-S [Recombinant]
Normalized name: ChAdOx1-S [recombinant]
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular administration of not less than 2.5 x 10\^8 infectious units
Study: NCT04964089
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection
Study: NCT01713803
Drug: Buprenorphine and naloxone
Normalized name: Buprenorphine and Naloxone Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06573138
Drug: Selinexor, anti-PD-1 antibody plus Golidocitinib
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
Study: NCT06395285
Drug: DF-003
Normalized name: DF-1001
DrugBank: DF-1001 (DB18231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
Study: NCT06572904
Drug: Tenoxicam Injectable Product
Normalized name: tenoxicam Injectable Product
DrugBank: Tenoxicam (DB00469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
Study: NCT06572904
Drug: Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly
Normalized name: Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
Study: NCT05511714
Drug: L-(11C) methionine
Normalized name: L-methionine ((11c)methyl)
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
Study: NCT06572319
Drug: Disitamab Vedotin(RC48) Plus Tratuzumab
Normalized name: Brentuximab Vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
Study: NCT05797805
Drug: Tegavivint
Normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle
Study: NCT05797805
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus pembrolizumab combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 of a 21-day cycle; Pembrolizumab will be administered on Day 1 of a 21- day cycle
Study: NCT06532539
Drug: Paclitaxel and Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used.
Study: NCT06532539
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
Study: NCT04887870
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
Study: NCT04887870
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study: NCT04887870
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
Study: NCT04887870
Drug: Enfortumab Vedotin-Ejfv
Normalized name: enfortumab vedotin-ejfv
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
Study: NCT04887870
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
Study: NCT05515432
Drug: Single oral dose of BAY3283142 IR (immediate release) tablet
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
Study: NCT00404157
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04857359
Drug: Dipraglurant
Normalized name: Dipraglurant
DrugBank: Dipraglurant (DB12733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 50mg and 100mg tablet